GlassScriptPhysician profile
Rajkumar Reyes Dasgupta
NPI 1437117421
$929,648.48
in general payments reported to CMS, 2019-2025
24 companies · $153K in 2025
The $153K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144K · 2020: $49K · 2021: $88K · 2022: $108K · 2023: $206K · 2024: $183K · 2025: $153K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $330K · Honoraria: $90K · Travel and Lodging: $70K · Consulting Fee: $30K · Food and Beverage: $13K · Education: $7,862 · Long Term Medical Supply Or Device Loan: $1,128 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $329,727.44 |
| Honoraria | $90,329.00 |
| Travel and Lodging | $69,830.45 |
| Consulting Fee | $29,967.50 |
| Food and Beverage | $12,736.25 |
| Education | $7,861.81 |
| Long Term Medical Supply Or Device Loan | $1,128.08 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $230,743.50 | 2020-2025 | Acthar, Terlivaz |
| Gilead Sciences, INC. | $148,810.44 | 2021-2024 | Veklury |
| Idorsia Pharmaceuticals US INC | $106,418.47 | 2022-2024 | Quviviq |
| Mallinckrodt Enterprises LLC | $91,169.35 | 2019 | |
| Merck Sharp & Dohme LLC | $87,780.53 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| La Jolla Pharmaceutical Company | $78,284.81 | 2021-2025 | Giapreza, Xacduro, Xerava |
| Ani Pharmaceuticals, INC. | $67,561.24 | 2024-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48,959.95 | 2019-2025 | Ofev, Jascayd |
| Glaxosmithkline, LLC. | $28,357.95 | 2024-2025 | Arexvy |
| Baxter Healthcare | $15,578.89 | 2022-2025 | Hillrom - Volara System, Hillrom - Vest System Model 205 Acute Care, Hillrom - Vest System Model 105 Home Care |
| Jazz Pharmaceuticals INC. | $8,194.68 | 2019 | |
| Melinta Therapeutics, LLC | $5,858.18 | 2019-2022 | |
| Advanced Respiratory, INC | $5,610.16 | 2019-2021 | |
| Modernatx, INC. | $4,640.45 | 2024 | Moderna Covid-19 Vaccine |
| Philips North America LLC | $1,169.83 | 2020-2024 | (8269) Dreamstation Cpap |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $202.54 | 2022-2023 | Dupixent |
| Genzyme Corporation | $75.12 | 2022-2025 | |
| Paratek Pharmaceuticals, INC. | $69.34 | 2024 | Nuzyra |
| Verona Pharma, INC. | $43.13 | 2025 | Ohtuvayre |
| Breathe Technologies, INC. | $30.95 | 2019 | |
| Aurinia Pharma U.S., INC. | $29.14 | 2025 | Lupkynis |
| Fisher & Paykel Healthcare INC | $28.09 | 2023 | Fisher & Paykel Healthcare |
| Alvogen INC | $18.04 | 2025 | Teriparatide |
| Harmony Biosciences LLC | $13.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajkumar Dasgupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.